Aldeyra Therapeutics

Aldeyra Therapeutics is a biotechnology company focused on developing and commercializing innovative medicines aimed at improving the lives of patients suffering from immune-mediated diseases. The company's lead investigational drug, reproxalap, is a first-in-class treatment that is in late-stage development for dry eye disease and allergic conjunctivitis. Additionally, Aldeyra is advancing other product candidates for a range of conditions, including proliferative vitreoretinopathy, primary vitreoretinal lymphoma, autoimmune diseases, and certain cancers. The company's efforts are dedicated to addressing unmet medical needs through the development of next-generation therapies.